Werewolf Therapeutics (HOWL) Stock Jumps 127% as Merger and $150M Raise Target CRPS Market

TLDR

• Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal, with the combined company trading as “AMBX” on Nasdaq
• A $150 million private placement was secured, co-led by RA Capital Management and Janus Henderson Investors
• The combined company will focus on neridronate, a drug targeting Complex Regional Pain Syndrome Type 1 (CRPS-1), with no current FDA-approved treatments
• Separately, Werewolf sold preclinical assets to EMD Serono for $28 million upfront, plus $5 million after technology transfer
• HOWL stock was up 127% in premarket trading Friday, changing hands at $0.9780

Werewolf Therapeutics (HOWL) stock surged 127% in premarket trading Friday, hitting $0.9780, after the company announced two separate deals on the same day.

Werewolf Therapeutics, Inc., HOWL

The first is a merger with Ambros Therapeutics in an all-stock transaction. The combined company will operate under the Ambros Therapeutics name and is expected to list on Nasdaq under the ticker “AMBX.”

… Continue reading the full article at the original source below.